These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 11729401)

  • 1. Reimbursement of enoxaparin for outpatient therapy. Proceedings of regional meetings.
    Manag Care; 1999 Dec; 8 Suppl():7-13. PubMed ID: 11729401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost comparison of at-home treatment of deep venous thrombosis with low molecular weight heparin to inpatient treatment with unfractionated heparin.
    Smith BJ; Weekley JS; Pilotto L; Howe T; Beven R
    Intern Med J; 2002; 32(1-2):29-34. PubMed ID: 11783670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.
    Huse DM; Cummins G; Taylor DC; Russell MW
    Am J Manag Care; 2002 Jan; 8(1 Suppl):S10-6. PubMed ID: 11822346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outpatient treatment of DVT in a 170,000-member HMO.
    Abu-Samrah S
    Manag Care; 1999 Dec; 8 Suppl():21. PubMed ID: 11729400
    [No Abstract]   [Full Text] [Related]  

  • 5. [Outpatient treatment of deep vein thrombosis with low-molecular-weight heparins. Experience from an open, prospective study in daily practice].
    Heidenreich C; Hohmann V; Bramlage P
    Med Klin (Munich); 2009 Jan; 104(1):20-7. PubMed ID: 19142593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
    Holzheimer RG
    Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reimbursement for outpatient therapy with enoxaparin.
    Dhamecha A; Yaron J
    Case Manager; 2002; 13(5):56-60; quiz 61. PubMed ID: 12239515
    [No Abstract]   [Full Text] [Related]  

  • 8. Deep venous thrombosis: outpatient therapy with low-molecular-weight heparin.
    Tapson VF
    Manag Care; 1999 Dec; 8 Suppl():2-6. PubMed ID: 11729399
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of different dose regimens of enoxaparin in deep vein thrombosis therapy in pregnancy.
    Narin C; Reyhanoglu H; Tülek B; Onoglu R; Ege E; Sarigül A; Yeniterzi M; Durmaz I
    Adv Ther; 2008 Jun; 25(6):585-94. PubMed ID: 18568442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin.
    Spyropoulos AC; Hurley JS; Ciesla GN; de Lissovoy G
    Chest; 2002 Jul; 122(1):108-14. PubMed ID: 12114345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis.
    Ramacciotti E; Araújo GR; Lastoria S; Maffei FH; Karaoglan de Moura L; Michaelis W; Sandri JL; Dietrich-Neto F;
    Thromb Res; 2004; 114(3):149-53. PubMed ID: 15342210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
    Lynd LD; Goeree R; Crowther MA; O'Brien BJ
    Can J Clin Pharmacol; 2007; 14(2):e215-26. PubMed ID: 18000316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic issues in the treatment and prevention of deep vein thrombosis from a managed care perspective.
    de Lissovoy G
    Am J Manag Care; 2001 Nov; 7(17 Suppl):S535-8; discussion S538-44. PubMed ID: 11732664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: a US perspective.
    de Lissovoy G; Subedi P
    Am J Manag Care; 2002 Dec; 8(12):1082-8. PubMed ID: 12500884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venous thromboembolism prophylaxis conversion in nonsurgical inpatients.
    Carroll DN; Hudson EB
    Ann Pharmacother; 2003 Sep; 37(9):1194-6. PubMed ID: 12921498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacoeconomics of deep vein thrombosis treatment.
    Shorr AF
    Am J Med; 2007 Oct; 120(10 Suppl 2):S35-41. PubMed ID: 17916458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of pulmonary embolism: The use of low-molecular-weight heparin in the inpatient and outpatient settings.
    Hull RD
    Thromb Haemost; 2008 Mar; 99(3):502-10. PubMed ID: 18327398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of the use of enoxaparin in non-ST-elevation acute coronary syndrome.
    Nutescu EA; Steinmetz Pater K
    Expert Opin Pharmacother; 2008 Jan; 9(1):95-105. PubMed ID: 18076341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism.
    Deitelzweig SB; Becker R; Lin J; Benner J
    Thromb Haemost; 2008 Nov; 100(5):810-20. PubMed ID: 18989525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.